ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Baclofen: Drug information

Baclofen: Drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Baclofen: Patient drug information" and "Baclofen: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Abrupt withdrawal (injection):

Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, which in rare cases has advanced to rhabdomyolysis, multiple organ-system failure, and death.

Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Advise patients and caregivers of the importance of keeping scheduled refill visits and educate them on the early symptoms of baclofen withdrawal. Give special attention to patients at apparent risk (eg, spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen). Consult the technical manual of the implantable infusion system for additional postimplant clinician and patient information.

Brand Names: US
  • Fleqsuvy;
  • Gablofen;
  • Lioresal;
  • Lyvispah;
  • Ozobax DS;
  • Ozobax [DSC]
Brand Names: Canada
  • APO-Baclofen;
  • Baclofen-10;
  • Baclofen-20;
  • Lioresal Intrathecal;
  • Lioresal [DSC];
  • MYLAN-Baclofen;
  • PMS-Baclofen;
  • RIVA-Baclofen
Pharmacologic Category
  • Skeletal Muscle Relaxant
Dosing: Adult

Dosage guidance:

Safety: A gradual dose taper (eg, over ≥1 to 2 weeks) is advised unless discontinuation is due to significant adverse effects or overdose-related emergencies; if withdrawal symptoms occur during discontinuation of chronic oral baclofen therapy, decrease dose at a more gradual rate (Ref). Abrupt discontinuation of oral or intrathecal baclofen may result in severe adverse effects, including multiple organ-system failure and death.

Alcohol use disorder

Alcohol use disorder (alternative agent) (off-label use):

Oral: Initial: 5 mg 3 times daily; may increase dose after 3 to 5 days based on response and tolerability to 10 mg 3 times daily; may increase further as needed to a maximum dose of 60 mg/day in divided doses (Ref).

Hiccups

Hiccups (off-label use):

Oral: Initial: 5 to 10 mg 3 times daily; may increase dose based on response and tolerability; usual maximum dose: 45 mg/day in divided doses (Ref).

Muscle spasm and/or musculoskeletal pain

Muscle spasm and/or musculoskeletal pain (adjunctive therapy) (off-label use):

Note: For skeletal muscle spasm and/or pain (eg, low back pain, neck pain) with muscle spasm, usually in combination with a nonsteroidal anti-inflammatory drug and/or acetaminophen (Ref). In general, muscle relaxants should be used temporarily (eg, for a few days or intermittently for a few days when needed) (Ref).

Oral: Initial: 5 to 10 mg 3 times daily as needed (Ref).

Spasticity

Spasticity:

Oral:

Granules: Initial: 5 mg 3 times daily; may increase by 5 mg per dose every 3 days based on response and tolerability; maximum dose: 80 mg per day (20 mg 4 times per day).

Solution, tablet: Initial: 5 mg 1 to 3 times daily; may increase by 5 mg per dose every 3 days based on response and tolerability; usual maximum dose: 80 mg/day in divided doses. Some patients may require doses up to 120 mg/day (Ref).

Suspension: Initial: 5 mg (1 mL) 3 times daily; may increase by 5 mg (1 mL) per dose every 3 days based on response and tolerability; usual maximum dose: 80 mg (16 mL) per day (20 mg [4 mL] 4 times per day).

Intrathecal:

Note: Use extreme caution when filling the pump; follow manufacturer instructions.

Screening dose: Initial bolus: 50 mcg over ≥1 minute then observe patient for 4 to 8 hours. A positive response consists of a significant decrease in muscle tone, frequency, and/or severity of spasms. If response is inadequate, may give 75 mcg as a second screening dose 24 hours after the first dose; observe patient for 4 to 8 hours. If response is still inadequate, may administer 100 mcg as a final screening dose 24 hours after the second dose. Patients not responding to screening dose of 100 mcg should not be considered for chronic infusion via implanted pump.

Initial total daily continuous infusion dose via implanted pump:

If screening dose provided positive response for >4 hours but <8 hours: Double the screening dose that gave a positive response and administer over 24 hours.

If screening dose provided positive response for >8 hours: Infuse a dose equivalent to the screening dose over 24 hours.

Initial titration after pump implantation: Do not increase dose in first 24 hours to allow steady state to be achieved; thereafter, initial dosage adjustments may be made by increasing daily dose by 10% to 30% (spasticity of spinal cord origin) or by 5% to 15% (spasticity of cerebral origin) once every 24 hours until satisfactory response.

Maintenance dose and titration: Daily dose may be increased periodically (eg, during pump refills) by 10% to 40% (maximum increase: 40%) for spasticity of spinal cord origin or by 5% to 20% (maximum increase: 20%) for spasticity of cerebral origin. Dose may also be decreased 10% to 20% for adverse effects. Most patients have been adequately maintained on 300 to 800 mcg daily (spasticity of spinal cord origin) or 90 to 703 mcg daily (spasticity of cerebral origin). Experience with doses >1,000 mcg daily is limited.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

Oral:

The following dosage adjustments have been recommended (Ref): Note: Kidney function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.

CrCl >80 mL/minute: No dosage adjustment necessary.

CrCl 50 to 80 mL/minute: Initial: 5 mg every 12 hours; titrate cautiously to effect; do not exceed 50 mg/day or ~66% of the usual maximum daily dose, whichever is less.

CrCl 30 to <50 mL/minute: Initial: 2.5 mg every 8 hours; titrate cautiously to effect; do not exceed 40 mg/day or ~50% of the usual maximum daily dose, whichever is less.

CrCl <30 mL/minute: Avoid use; in some patients, even low initial doses for short duration have led to toxicity (Ref). If baclofen use cannot be avoided, initiate at a low dose (eg, 2.5 mg every 12 hours or less); titrate with extreme caution to effect; do not exceed 20 mg/day or ~33% of the usual maximum daily dose, whichever is less.

Intrathecal: Mild to severe impairment: There are no specific dosage adjustments recommended. However, baclofen is primarily eliminated by the kidney; use with caution; dosage reduction may be necessary.

Hemodialysis, intermittent (thrice weekly): Dialyzable (1 case report of 79% removal with a 4-hour session) (Ref):

Oral, intrathecal: Avoid use. Numerous case reports and 1 population-based cohort study have demonstrated significant adverse events related to chronic maintenance dosing and unintentional overdoses (Ref). If baclofen use cannot be avoided, initiate at a low dose (eg, 2.5 mg orally every 12 hours or less); titrate with extreme caution to effect (Ref).

Peritoneal dialysis:

Oral, intrathecal: Avoid use. Baclofen clearance by peritoneal dialysis has not been characterized. Multiple case reports have reported hospitalization for encephalopathy (Ref). If baclofen use cannot be avoided, initiate at a low dose (eg, 2.5 mg orally every 12 hours or less); titrate with extreme caution to effect (Ref).

CRRT:

Oral, intrathecal: Avoid use. If baclofen use cannot be avoided, initiate at a low dose; titrate cautiously to effect (expert opinion). Note: CRRT data are primarily limited to the treatment of acute baclofen intoxication, which have demonstrated significant increases in baclofen clearance (Ref). However, because CRRT is often used short term and in acutely ill patients, dose increases in response to increased clearance are not recommended unless clinically indicated (eg, increased spasticity) (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration):

Oral, intrathecal: Avoid use. Pharmacokinetics of baclofen in patients receiving PIRRT have not been well characterized (Ref).

Dosing: Hepatic Impairment: Adult

Oral and intrathecal: There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Older Adult

Oral: Refer to adult dosing; use with caution. If benefits are not observed, withdraw the drug slowly.

Dosing: Pediatric

(For additional information see "Baclofen: Pediatric drug information")

Dosage guidance:

Safety: Gradual dose reduction is advised unless discontinuation is due to significant adverse effects or overdose-related emergencies; chronic oral baclofen therapy should be discontinued slowly (eg, over at least 1 to 2 weeks or longer if withdrawal symptoms occur) (Ref). Abrupt discontinuation of oral or intrathecal baclofen may result in severe adverse effects, including multiple organ system failure and death (Ref).

Dosage form information: Baclofen is available as both oral solutions and oral suspensions; concentration varies by product; use extra caution during product selection and preparation and verify correct product/concentration is chosen.

Spasticity

Spasticity:

Oral: Note: Dose-related side effects (eg, sedation) may be minimized by slow titration; lower initial doses than described below (2.5 to 10 mg administered daily) may be used with subsequent titration to 8 hourly doses (Ref).

Infants ≥4 months and Children <2 years: Very limited data available: Oral: Usual dose: 10 to 20 mg/day in divided doses every 8 hours; begin at low end of range and titrate dose to patient response (Ref); titration intervals of every 7 days have been used in pediatric patients ≥2 years (Ref). Maximum daily dose: 40 mg/day (Ref). Dosing based on a retrospective study of 87 patients (age 9 ± 6 years; range: 0.4 to 23.5 years) with spasticity due to cerebral palsy or traumatic brain injury (Ref). Note: To minimize dose-related side effects (eg, sedation), lower initial doses (ie, 2.5 mg once to 3 times daily) may be considered and have been reported in pediatric patients >2 years (Ref).

Children 2 to 7 years: Limited data available: Oral: Initial: 2.5 mg 3 times daily; titrate dose by 5 mg increments at weekly intervals to patient response; usual dose: 20 to 40 mg/day. Maximum daily dose: 60 mg/day (Ref). Note: Initial doses of 5 to 10 mg/day divided every 8 hours and more frequent titration intervals (ie, every 3 days) have also been described (Ref).

Children ≥8 years and Adolescents: Limited data available in children <12 years: Oral: Initial: 5 mg 3 times daily; titrate dose to patient response every 3 to 7 days to usual dose of 30 to 40 mg/day; some patients ≥12 years may require every-6-hour dosing; maximum daily dose: 80 mg/day (Ref). Note: Lower initial doses (5 to 10 mg/day) have also been described (Ref). Higher maximum daily doses (up to 200 mg/day) have been described in some patients in a retrospective review; usually the higher doses were needed over time (Ref).

Intrathecal: Note: Dosage adjustments may be required often during the first few months of therapy to adjust for lifestyle changes due to alleviation of spasticity. Maintain lowest dose that produces adequate response. Most patients require gradual increases over time to maintain optimal response. Sudden large requirements for a dose increase may indicate a catheter complication (eg, kink, dislodgement). Titrate dose to allow sufficient muscle tone and occasional spasms to optimize activities of daily living, support circulation, and possibly prevent deep vein thrombosis (DVT) formation. Use extreme caution when filling the pump; follow manufacturer instructions carefully. With chronic therapy, 5% to 10% of patients will become refractory to dose adjustments; may consider a drug holiday (hospitalized patients only) with a gradual withdrawal over 2 to 4 weeks and use of alternative spasticity management methods. Following the drug holiday, intrathecal baclofen may be resumed at the initial continuous infusion dose. Limited data available in children <4 years; dosing for this age group based on expert consensus recommendations (Ref).

Screening dose:

Children <4 years: Limited data available: Intrathecal: Initial: 25 mcg; if response is inadequate, double the initial dose and administer 24 hours after the first dose (Ref).

Children ≥4 years and Adolescents: Intrathecal: Initial: 50 mcg (1 mL) for 1 dose; for patients considered very small for age, a 25 mcg initial screening dose may be considered; following administration of screening dose, observe patient for 4 to 8 hours. A positive response consists of a significant decrease in muscle tone and/or frequency and/or severity of spasms. If response is inadequate, may increase screening dose in 25 mcg increments every 24 hours until a 4- to 8-hour positive clinical response is demonstrated or 100 mcg/dose is given. Patients not responding to screening dose of 100 mcg should not be considered for chronic infusion/implanted pump (Ref).

Initial dose titration following pump implant: Children and Adolescents: After positive response to screening dose, a maintenance intrathecal infusion can be administered via an implanted intrathecal pump.

Initial total daily dose via pump: Children and Adolescents: Intrathecal: Double the screening dose that gave a positive response and administer over 24 hours, unless efficacy of the bolus dose was maintained for >8 hours or if negative reactions to the screening test dose (change in mental status, loss of function, or change in vital signs) occurred, then infuse a dose equivalent to the screening dose over 24 hours (Ref).

Do not increase dose in first 24 hours (to allow steady state to be achieved); thereafter, increase daily dose slowly by 5% to 15% once every 24 hours until satisfactory response is achieved; usual range: 50 to 100 mcg daily (Ref).

Maintenance dose titration (Ref):

Children and Adolescents: Intrathecal:

Inpatient titration: Daily dose may be increased periodically (eg, during pump refills) by 10% to 20% of dose; usual dose change is 50 mcg; maximum increment change: 100 mcg. Note: At lower doses, a 20% increase may be reasonable, but at higher doses a 20% increase may be excessive. Daily dose may be decreased by 10% to 20% for adverse effects.

Outpatient titration: Daily dose may be increased periodically (eg, during pump refills) by 5% to 10% of daily dose (usual dose change is 25 mcg). Daily dose may be decreased by 10% to 20% for adverse effects.

Usual maintenance dose: Children and Adolescents: Intrathecal: 100 to 2,000 mcg daily (Ref); the manufacturer provides the following:

Children 4 to 12 years: Intrathecal: 24 to 1,199 mcg daily (average: 274 mcg/day).

Children ≥12 years and Adolescents: Intrathecal: 90 to 703 mcg daily; daily doses have ranged from 22 to 1,400 mcg; experience with doses >1,000 mcg daily is limited.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Oral: There are no dosage adjustments provided in the manufacturer's labeling; however, baclofen is primarily renally eliminated; use with caution; dosage reduction may be necessary.

Intrathecal: Children and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, baclofen is primarily renally eliminated; use with caution; dosage reduction may be necessary.

Dosing: Hepatic Impairment: Pediatric

Oral, Intrathecal: There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions (Significant): Considerations
CNS effects

CNS effects may include confusion, dizziness, drowsiness, sedation, asthenia, nausea, and vomiting (Ref). CNS effects may impair physical or mental abilities and be additive to alcohol and other CNS depressants (eg, opioids, benzodiazepines). Multiple cases describing neurotoxicity due to oral baclofen accumulation in adult patients with varying levels of renal impairment have been reported in the literature. In one study of 6,469 older adults on dialysis (360 receiving baclofen), 7.2% of patients started on baclofen were hospitalized for encephalopathy (median time to hospitalization of 3 days) compared to <0.1% of patients not receiving baclofen (Ref).

Mechanism: Dose-related; related to the pharmacologic action. Reduces the release of excitatory neurotransmitters by binding to the GABA-B presynaptic receptors within the brain stem, dorsal horn of the spinal cord, and other CNS sites (Ref).

Risk factors:

• Oral doses >60 mg/day (Ref)

• Oral (vs intrathecal) administration (Ref)

• Severe kidney dysfunction (eGFR <30 mL/minute/1.73m2) (Ref)

Withdrawal effects

Intrathecal baclofen: Abrupt withdrawal of intrathecal baclofen has been associated with altered mental status, exaggerated rebound spasticity, high fever, and muscle rigidity (which in rare cases has advanced to rhabdomyolysis, multiple organ-system failure, and death) (Ref).

Oral baclofen: Abrupt withdrawal of oral baclofen has been associated with altered mental status, exaggerated rebound spasticity, hallucination, high fever, hypertension, hyperthermia, muscle rigidity, tachycardia, and seizure. Other symptoms include agitation, confusion, delusions, insomnia, and paranoid ideation (Ref). Neonatal withdrawal has also been reported in neonates whose mothers were treated with oral baclofen throughout pregnancy (Ratnayaka 2001).

Mechanism: Withdrawal; related to the release of excitatory neurotransmitters (Ref).

Onset: Rapid; symptoms appear within hours to a few days following interruption of intrathecal therapy (Ref) and within 12 to 72 hours after discontinuation of oral therapy (Ref). Neonatal withdrawal has been reported within hours to days after delivery.

Risk factors:

• Pump malfunction or removal (eg, battery failure, catheter displacement, infection, intrathecal mass) (Ref)

• Preventable human errors (eg, programming or pump refill errors, oral baclofen administration or refill errors) (Ref)

• Patients with spinal cord injuries at T-6 or above, communication difficulties, or history of withdrawal symptoms from intrathecal or oral baclofen

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Gastrointestinal: Nausea (≤12%), vomiting (≤11%)

Nervous system: Asthenia (≤15%), confusion (≤11%), dizziness (2% to 15%), drowsiness (≤63%), headache (2% to 11%), hypotonia (2% to 35%)

1% to 10%:

Cardiovascular: Hypotension (≤9%), peripheral edema (2% to 3%)

Dermatologic: Pruritus (4%), urticaria (≤1%)

Gastrointestinal: Constipation (≤6%), diarrhea (≤2%), sialorrhea (3%), xerostomia (≤3%)

Genitourinary: Difficulty in micturition (2%), erectile dysfunction (≤2%), urinary frequency (≤6%), urinary incontinence (≤2%), urinary retention (≤8%)

Nervous system: Agitation (≤1%), changes in thinking (≤1%), chills (≤1%), coma (≤2%), depression (2%), fatigue (2% to 4%), insomnia (≤7%), pain (≤4%), paresthesia (≤7%), seizure (≤10%; including exacerbation of epilepsy), speech disturbance (≤4%), tremor (≤1%)

Neuromuscular & skeletal: Back pain (≤2%)

Ophthalmic: Amblyopia (≤2%)

Respiratory: Dyspnea (≤1%), hypoventilation (≤4%), pneumonia (≤2%)

Miscellaneous: Accidental injury (≤4%)

<1%:

Cardiovascular: Ankle edema, bradycardia, chest pain, hypertension, palpitations, syncope, vasodilation

Dermatologic: Alopecia, contact dermatitis, dermal ulcer, hyperhidrosis, skin rash

Endocrine & metabolic: Weight gain

Gastrointestinal: Abdominal pain, anorexia, dysgeusia, dysphagia, fecal incontinence, gastrointestinal hemorrhage, occult blood in stools, tongue irritation

Genitourinary: Dysuria, hematuria, inhibited ejaculation, nocturia, oliguria, vaginitis

Hematologic & oncologic: Carcinoma, leukocytosis, petechial rash

Nervous system: Akathisia, amnesia, anxiety, ataxia, dysarthria, dysautonomia, euphoria, excitement, hallucination, hyporeflexia, hypothermia, hysteria, malaise, opisthotonus, personality disorder, slurred speech

Neuromuscular & skeletal: Dystonia, muscle rigidity, myalgia

Ophthalmic: Accommodation disturbance, blurred vision, diplopia, miosis, mydriasis, nystagmus disorder, strabismus

Otic: Tinnitus

Renal: Nephrolithiasis

Respiratory: Apnea, hyperventilation, nasal congestion

Miscellaneous: Fever (can be high fever with drug withdrawal)

Frequency not defined:

Endocrine & metabolic: Increased serum glucose

Hepatic: Increased serum alkaline phosphatase, increased serum aspartate aminotransferase

Nervous system: Withdrawal syndrome

Postmarketing:

Cardiovascular: Deep vein thrombophlebitis (Carda 2008), pulmonary embolism (Carda 2008)

Endocrine & metabolic: Decreased libido (Hornyak 2005), weight loss (Arima 2010)

Gastrointestinal: Intestinal obstruction (Karthikeyan 2015), paralytic ileus (Morant 2006)

Genitourinary: Abnormal orgasm (Hornyak 2005; Saval 2008), priapism, sexual disorder (McGehee 2006; Saval 2008)

Nervous system: Delirium (Chauvin 2020), disorientation (Chauvin 2020), neonatal withdrawal (Ratnayaka 2001), suicidal ideation (Pelissier 2017; WeiBhaar 2012), transient ischemic attacks (Chauvin 2020)

Neuromuscular & skeletal: Scoliosis (Panagopoulos 2020), scoliosis progression (Ginsburg 2007; Walker 2017)

Contraindications

Hypersensitivity to baclofen or any component of the formulation

Intrathecal formulation: IV, IM, SubQ, or epidural administration

Warnings/Precautions

Concerns related to adverse effects:

• Intrathecal mass: Cases (most from pharmacy compounded preparations) of intrathecal mass formation at the implanted catheter tip have been reported; patients may experience worsening or return of spasticity, pain, inadequate response to dose adjustments, and/or neurological deficit/dysfunction. Neurosurgical evaluation and/or an appropriate imaging study should be considered if a mass is suspected.

• Urinary retention: May cause acute urinary retention (may be related to underlying disease); use with caution in patients with urinary obstruction.

Disease-related concerns:

• Autonomic dysreflexia: Use with caution in patients with a history of autonomic dysreflexia; presence of nociceptive stimuli or abrupt baclofen withdrawal may cause an autonomic dysreflexic episode.

• Gastrointestinal disorders: Use with caution in patients with peptic ulcer disease, decreased GI motility, and/or GI obstructive disorders.

• Psychiatric disease: Use with caution in patients with psychotic disorders, schizophrenia, or confusional states; may cause exacerbation of condition.

• Renal impairment: Use with caution in patients with renal impairment; baclofen is eliminated primarily unchanged via the kidneys.

• Respiratory disease: Use with caution in patients with respiratory disease.

• Seizure disorder: Loss of seizure control has been reported in patients treated with baclofen; use with caution and monitor patients with a history of seizure disorder.

Special populations:

• Older adult: Use with caution in elderly patients; may be more sensitive to adverse CNS effects, especially at higher doses.

• Neonates: Neonatal withdrawal symptoms (eg, increased muscle tone, jitteriness, tremor, seizure), beginning hours to days after delivery, have been reported in neonates born to mothers treated with baclofen throughout pregnancy.

• Pediatric: Intrathecal: Children should be of sufficient body mass to accommodate the implantable pump for chronic infusion.

Dosage form specific issues:

• Oral products: Multiple products available; ensure appropriate strength and dose of the oral formulation prior to administering, dispensing, and prescribing; oral suspension is a concentrated formulation.

Other warnings/precautions:

• Appropriate use: Intrathecal: For use only in an FDA-approved implantable pump for intrathecal baclofen administration; health care providers should be experienced with chronic intrathecal infusion therapy and resuscitative equipment should be readily available. Ensure patient is infection-free and then evaluate patient's response to bolus intrathecal injection (screening phase) prior to implanting pump. Monitor closely during the initial phase of pump use and when adjusting the dosing rate and/or the concentration in the reservoir. Educate patients and caregivers on proper home care of the pump and insertion site. Use extreme caution when filling an implantable pump; pumps should only be refilled through the reservoir refill septum. Inadvertent injection into the subcutaneous tissue can occur if the reservoir refill septum is not properly accessed. Some pumps are equipped with a catheter access port that allows direct access to the intrathecal catheter; direct injection into this catheter access port or inadvertent injection into the subcutaneous tissue may cause a life-threatening overdose. Except in overdose related emergencies, intrathecal baclofen should be reduced slowly if discontinuation is necessary.

• Appropriate use: Oral: Efficacy of oral baclofen has not been established in patients with Parkinson disease or cerebral palsy; therefore, use is not recommended. Use caution in patients with a history of stroke; poor tolerability to baclofen without significant benefit has been observed. Not indicated for spasticity associated with rheumatic disorders. Use with caution when spasticity is utilized to sustain upright posture and balance in locomotion, or when spasticity is necessary to obtain increased function.

• Overdose: Intrathecal use: Monitor closely for signs and symptoms of overdose, which may appear suddenly or insidiously, especially during the initial screening and dose-titration phase of treatment, and during reintroduction of therapy after a period of interruption. Signs/symptoms of overdose may include drowsiness, dizziness, somnolence, hypothermia, respiratory depression, seizures, rostral progression of hypotonia, and loss of consciousness progressing to coma. If overdose is suspected, patient should be evaluated immediately in a hospital setting and the pump reservoir emptied.

Dosage Forms Considerations

First-Baclofen suspension is a compounding kit. Refer to manufacturer’s labeling for compounding instructions.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Packet, Oral:

Lyvispah: 5 mg (90 ea [DSC]) [contains saccharin sodium]

Lyvispah: 5 mg (90 ea) [contains saccharin sodium; strawberry flavor]

Lyvispah: 10 mg (90 ea [DSC]) [contains saccharin sodium]

Lyvispah: 10 mg (90 ea) [contains saccharin sodium; strawberry flavor]

Lyvispah: 20 mg (90 ea [DSC]) [contains saccharin sodium]

Lyvispah: 20 mg (90 ea) [contains saccharin sodium; strawberry flavor]

Solution, Intrathecal:

Lioresal: 0.05 mg/mL (1 mL)

Lioresal: 10 mg/20 mL (20 mL); 10 mg/5 mL (5 mL); 40 mg/20 mL (20 mL) [latex free]

Generic: 10 mg/20 mL (20 mL); 40 mg/20 mL (20 mL); 20,000 mcg/20 mL (20 mL)

Solution, Intrathecal [preservative free]:

Gablofen: 10,000 mcg/20 mL (20 mL); 20,000 mcg/20 mL (20 mL) [antioxidant free]

Gablofen: 40,000 mcg/20 mL (20 mL)

Lioresal: 0.05 mg/mL (1 mL); 40 mg/20 mL (20 mL) [antioxidant free]

Lioresal: 10 mg/20 mL (20 mL); 10 mg/5 mL (5 mL) [antioxidant free, pyrogen free]

Generic: 40,000 mcg/20 mL (20 mL); 10 mg/20 mL (20 mL); 40 mg/20 mL (20 mL); 20,000 mcg/20 mL (20 mL)

Solution, Oral:

Ozobax: 5 mg/5 mL (473 mL [DSC]) [contains methylparaben, propylparaben; grape flavor]

Ozobax DS: 10 mg/5 mL (237 mL, 473 mL) [contains methylparaben, propylparaben]

Generic: 5 mg/5 mL (473 mL); 10 mg/5 mL (237 mL, 473 mL)

Solution Prefilled Syringe, Intrathecal [preservative free]:

Gablofen: 50 mcg/mL (1 mL) [antioxidant free, latex free]

Gablofen: 20,000 mcg/20 mL (20 mL) [antioxidant free]

Gablofen: 10,000 mcg/20 mL (20 mL); 40,000 mcg/20 mL (20 mL) [antioxidant free, pyrogen free]

Generic: 50 mcg/mL (1 mL)

Suspension, Oral:

Fleqsuvy: 25 mg/5 mL (120 mL, 300 mL) [contains fd&c red #40 (allura red ac dye), propylene glycol, quinoline yellow (d&c yellow #10), sodium benzoate]

Generic: 25 mg/5 mL (120 mL, 250 mL, 300 mL)

Tablet, Oral:

Generic: 5 mg, 10 mg, 15 mg, 20 mg

Generic Equivalent Available: US

May be product dependent

Pricing: US

Pack (Lyvispah Oral)

5 mg (per each): $4.32

10 mg (per each): $4.32

20 mg (per each): $4.32

Solution (Baclofen Intrathecal)

10 mg/20 mL (per mL): $7.08 - $11.60

40 mg/20 mL (per mL): $28.38 - $46.39

Solution (Baclofen Oral)

5 mg/5 mL (per mL): $1.31

10 mg/5 mL (per mL): $3.72

Solution (Gablofen Intrathecal)

10000 mcg/20 mL (per mL): $14.18

20000 mcg/20 mL (per mL): $28.35

40000 mcg/20 mL (per mL): $56.71

Solution (Lioresal Intrathecal)

0.05 mg/mL (per mL): $39.56

10 mg/20 mL (per mL): $14.18

10 mg/5 mL (per mL): $56.71

40 mg/20 mL (per mL): $56.71

Solution (Ozobax DS Oral)

10 mg/5 mL (per mL): $4.14

Solution Prefilled Syringe (Baclofen Intrathecal)

50 mcg/mL (per mL): $52.80

Solution Prefilled Syringe (Gablofen Intrathecal)

50 mcg/mL (per mL): $105.50

10000 mcg/20 mL (per mL): $15.23

20000 mcg/20 mL (per mL): $30.46

40000 mcg/20 mL (per mL): $61.00

Suspension (Baclofen Oral)

25 mg/5 mL (per mL): $7.26

Suspension (Fleqsuvy Oral)

25 mg/5 mL (per mL): $7.26

Tablets (Baclofen Oral)

5 mg (per each): $0.34 - $1.54

10 mg (per each): $0.14 - $2.47

15 mg (per each): $2.60

20 mg (per each): $0.16 - $5.13

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intrathecal:

Lioresal Intrathecal: 500 mcg/mL ([DSC]); 2000 mcg/mL ([DSC]); 0.05 mg/mL (1 mL)

Generic: 500 mcg/mL (20 mL); 0.05 mg/mL (1 mL); 2 mg/mL (5 mL, 20 mL)

Tablet, Oral:

Lioresal: 10 mg [DSC]

Generic: 10 mg, 20 mg

Administration: Adult

Intrathecal: For screening dosages, administer as a bolus injection (50 mcg/mL concentration) by barbotage into the subarachnoid space over at least 1 minute, followed by maintenance continuous infusion. Do not administer intrathecal formulation IV, IM, SUBQ, or epidurally.

Oral:

Granules: Contents of packet may be emptied into the mouth and swallowed or may be mixed with up to 15 mL of liquid or soft food (eg, applesauce, yogurt, pudding). If mixing with food, entire mixture should be consumed within 2 hours of mixing. If multiple packets are needed to complete dose, each packet must be mixed with separate volume of liquid or food.

Solution, suspension: Administer without regards to meals. Shake suspension well; use a calibrated measuring device to administer; do not use a household teaspoon or tablespoon.

En teral feeding tube:

The following recommendations are based upon the best available evidence and clinical expertise. Senior editorial team: Joseph I. Boullata, PharmD, RPh, CNS-S, FASPEN, FACN; Peggi A. Guenter PhD, RN, FASPEN; Kathleen Gura, PharmD, BCNSP, FASHP, FASPEN, FPPA, FMSHP; Mark G. Klang MS, RPh, BCNSP, PhD, FASPEN; Linda Lord, NP, ACNP-BC, CNSC, FASPEN.

Oral granules:

Gastric (eg, NG, percutaneous endoscopic gastrostomy [PEG]) or post-pyloric (eg, jejunostomy) tubes (≥8 French): Mix packet contents with 15 mL of purified water until granules wetted. Draw up suspension of granules/liquid into enteral dosing syringe and administer via feeding tube; repeat process if multiple packets are needed to complete a dose. Administer within 2 hours of initial mixing. If mixture in enteral dosing syringe is allowed to stand for ≥15 minutes prior to administration, invert syringe 3 times to ensure baclofen is mixed (Ref).

General guidance: Hold enteral nutrition during baclofen administration (Ref). Flush feeding tube with an appropriate volume of purified water before administration (Ref). Following administration, rinse container used for preparation with purified water; draw up rinse and administer contents to ensure delivery of entire dose (Ref). Flush feeding tube with an appropriate volume of purified water and restart enteral nutrition (Ref).

Oral solution (commercially available):

Gastric tubes (eg, NG, PEG): Dilute with equal volume of purified water prior to administering to reduce osmolality and viscosity; draw up diluted solution into enteral dosing syringe and administer via feeding tube (Ref).

General guidance: Hold enteral nutrition during baclofen administration (Ref). Flush feeding tube with an appropriate volume of purified water before administration (Ref). Following administration, rinse container used for preparation with purified water; draw up rinse and administer contents to ensure delivery of entire dose (Ref). Flush feeding tube with an appropriate volume of purified water and restart enteral nutrition (Ref).

Oral suspension (commercially available): Enteral administration of oral suspension has not been evaluated.

Oral tablets:

Gastric (eg, NG, PEG) or post-pyloric (eg, jejunal) tubes (≥8 French): Crush tablets into a fine powder and disperse in purified water (≥10 mL) prior to administration, then draw up mixture into enteral dosing syringe and administer via feeding tube (Ref).

General guidance: Hold enteral nutrition during baclofen administration (Ref). Flush feeding tube with an appropriate volume of purified water before administration (Ref). Following administration, rinse container used for preparation with purified water; draw up rinse and administer contents to ensure delivery of entire dose (Ref). Flush feeding tube with an appropriate volume of purified water and restart enteral nutrition (Ref).

Note: Recommendations may not account for differences in inactive ingredients, osmolality, or other formulation properties among manufacturers.

Administration: Pediatric

The following feeding tube recommendations are based upon the best available evidence and clinical expertise. Senior editor panel: Joseph I. Boullata, PharmD, RPh, CNS-S, FASPEN, FACN; Peggi A. Guenter, PhD, RN, FASPEN; Kathleen Gura, PharmD, BCNSP, FASHP, FASPEN, FPPA, FMSHP; Mark G. Klang, MS, RPh, BCNSP, PhD, FASPEN; Linda Lord, NP, ACNP-BC, CNSC, FASPEN.

Note: Recommendations may not account for differences in inactive ingredients, osmolality, or other formulation properties among manufacturers.

Oral:Administer without regard to meals. If nausea occurs, may administer with food or milk (Ref).

Oral liquid: Baclofen is available as both oral solutions and oral suspensions; concentration varies by product; use extra caution during product selection and preparation and verify correct product/concentration is chosen.

Oral solution (commercially available): Administer with a calibrated measuring device; do not use a household teaspoon (overdosage may occur).

Administration via feeding tube:

Gastric tubes (eg, NG, percutaneous endoscopic gastrostomy [PEG]): Dilute oral solution with equal volume of purified water prior to administering to reduce osmolality and viscosity; draw up diluted solution into enteral dosing syringe and administer via feeding tube (Ref).

General guidance: Hold enteral nutrition during baclofen administration (Ref). Flush feeding tube with an appropriate volume of purified water before administration (Ref); consult ASPEN recommendations (Ref) or institution-specific protocols for appropriate flush volume. Following administration, rinse container used for preparation with purified water; draw up rinse and administer contents to ensure delivery of entire dose (Ref). Flush feeding tube with an appropriate volume of purified water and restart enteral nutrition (Ref).

Oral suspension (commercially available) : Shake well prior to administration. Administer with a calibrated measuring device; do not use a household teaspoon (overdosage may occur).

Administration via feeding tube: Enteral feeding tube administration of oral suspension has not been evaluated.

Oral granules: Contents of packet may be emptied into the mouth and swallowed or may be mixed with up to 15 mL of liquid or soft food (eg, applesauce, yogurt, pudding). If mixing with food, entire mixture should be consumed within 2 hours of mixing. If multiple packets are needed to complete dose, each packet must be mixed with separate volume of liquid or food.

Administration via feeding tube:

Gastric (eg, NG, PEG) or post-pyloric (eg, jejunostomy) tubes (≥8 French): Mix content of each oral granules packet with 15 mL of purified water until granules wetted. Draw up suspension of granules/liquid into enteral dosing syringe and administer via feeding tube; repeat process if multiple packets are needed to complete a dose. Administer within 2 hours of initial mixing. If mixture in enteral dosing syringe is allowed to stand for ≥15 minutes prior to administration, invert syringe 3 times to ensure baclofen is mixed (Ref).

General guidance: Hold enteral nutrition during baclofen administration (Ref). Flush feeding tube with an appropriate volume of purified water before administration (Ref); consult ASPEN recommendations (Ref) or institution-specific protocols for appropriate flush volume. Following administration, rinse container used for preparation with purified water; draw up rinse and administer contents to ensure delivery of entire dose (Ref). Flush feeding tube with an appropriate volume of purified water and restart enteral nutrition (Ref).

Oral tablets:

Administration via feeding tube:

Gastric (eg, NG, PEG) or post-pyloric (eg, jejunal) tubes (≥8 French): Crush tablet(s) to a fine powder and disperse in purified water (≥10 mL) prior to administration; then draw up mixture into enteral dosing syringe and administer via feeding tube (Ref).

General guidance: Hold enteral nutrition during baclofen administration (Ref). Flush feeding tube with an appropriate volume of purified water before administration (Ref); consult ASPEN recommendations (Ref) or institution-specific protocols for appropriate flush volume. Following administration, rinse container used for preparation with purified water; draw up rinse and administer contents to ensure delivery of entire dose (Ref). Flush feeding tube with an appropriate volume of purified water and restart enteral nutrition (Ref).

Parenteral:Intrathecal: Screening dosage: Administer as a bolus injection by barbotage into the subarachnoid space over at least 1 minute, followed by maintenance infusion via implantable infusion pump; do not abruptly discontinue intrathecal baclofen administration. Do not administer intrathecal formulation IV, IM, SUBQ, or epidurally.

Use: Labeled Indications

Spasticity:

Oral:

Solution (Ozobax), tablet: Management of reversible spasticity associated with multiple sclerosis or spinal cord lesions.

Granules (Lyvispah), solution (Ozabax DS), suspension (Fleqsuvy): Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; may also be of some value in patients with spinal cord injuries and other spinal cord diseases.

Intrathecal: Management of severe spasticity of spinal cord origin (eg, spinal cord injury, multiple sclerosis) or cerebral origin (eg, cerebral palsy, traumatic brain injury) in patients ≥4 years of age; may be considered as an alternative to destructive neurosurgical procedures.

Limitations of use: Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long-term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS adverse effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least 1 year after the injury before consideration of long-term intrathecal baclofen therapy.

Use: Off-Label: Adult

Alcohol use disorder; Hiccups; Muscle spasm and/or musculoskeletal pain

Medication Safety Issues
Sound-alike/look-alike issues:

Baclofen may be confused with Bactroban

Lioresal may be confused with lisinopril, Lotensin

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes (epidural and intrathecal medications) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care Settings).

Administration issues:

Different concentrations of the oral liquid are available; ensure appropriate strength and dose of oral liquid prior to administering, dispensing, and prescribing.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider therapy modification

Botulinum Toxin-Containing Products: Muscle Relaxants (Centrally Acting) may enhance the adverse/toxic effect of Botulinum Toxin-Containing Products. Specifically, the risk for increased muscle weakness may be enhanced. Risk C: Monitor therapy

Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification

Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy

Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider therapy modification

Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. Risk C: Monitor therapy

DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification

Esketamine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. Risk X: Avoid combination

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider therapy modification

Ixabepilone: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Lacidipine: Baclofen may enhance the hypotensive effect of Lacidipine. Risk C: Monitor therapy

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification

Lisuride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Loxapine: CNS Depressants may enhance the CNS depressant effect of Loxapine. Risk D: Consider therapy modification

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider therapy modification

Metoclopramide: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Nabilone: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products. Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use Risk D: Consider therapy modification

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy

Procarbazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider therapy modification

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Tolperisone: May enhance the adverse/toxic effect of Muscle Relaxants (Centrally Acting). Management: Monitor for increased sedation or CNS effects if tolperisone is combined with other centrally acting muscle relaxants. Consider decreasing the tolperisone dose if these agents are combined. Risk D: Consider therapy modification

Tricyclic Antidepressants: May enhance the adverse neuromuscular effect of Baclofen. Baclofen may enhance the CNS depressant effect of Tricyclic Antidepressants. Risk C: Monitor therapy

Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Urapidil: Baclofen may enhance the hypotensive effect of Urapidil. Risk C: Monitor therapy

Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider therapy modification

Pregnancy Considerations

Late-onset neonatal withdrawal may occur following in utero exposure. Feeding difficulties, high-pitched cry, hyperthermia, hypertonicity, loose stools, tremors, and seizures have been reported in newborns following maternal use of oral baclofen throughout pregnancy (Duncan 2013; Freeman 2016; Ratnayaka 2001). Use of intrathecal baclofen in pregnant females has been described (Dalton 2008; Hara 2018; Méndez-Lucena 2016; Tandon 2010). Maternal plasma concentrations following administration of intrathecal baclofen are significantly less than those with oral doses; exposure to the fetus is expected to be limited and adverse neonatal events have not been noted in available reports (Morton 2009).

Breastfeeding Considerations

Baclofen is present in breast milk.

The relative infant dose (RID) of oral baclofen is 5% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 80 mg/day.

In general, breastfeeding is considered acceptable when the RID of a medication is <10% (Anderson 2016; Ito 2000).

The RID of baclofen was calculated using a milk concentration of 0.38 mcg/mL, providing an estimated daily infant dose via breast milk of 0.057 mg/kg/day. This milk concentration was obtained following maternal administration of oral baclofen 20 mg four times a day, shortly after birth (Lin 2014). A case report notes breast milk concentrations following maternal use of intrathecal baclofen 330 mcg/day throughout pregnancy were 0.617 ng/mL (Hara 2018). Adverse events were not observed in a breastfed infant following maternal use of intrathecal baclofen 200 mcg/day throughout pregnancy and postpartum (breast milk concentrations not sampled) (Morton 2009).

Information related to milk concentrations is limited (Eriksson 1981; Lin 2014). Withdrawal symptoms may occur in a breastfed infant when maternal baclofen is discontinued or breastfeeding is stopped. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Monitoring Parameters

Regular EEG in patients with epilepsy (loss of seizure control has been reported); monitor for signs and symptoms of baclofen withdrawal (oral or intrathecal; eg, altered mental status, exaggerated rebound spasticity, hallucination, high fever, hypertension, hyperthermia, muscle rigidity, tachycardia, seizure, agitation, confusion, delusions, insomnia, and paranoid ideation); prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms; monitor closely during the initial phase of pump use and when adjusting the dosing rate and/or the concentration in the reservoir. monitor closely for signs and symptoms of overdose (eg, drowsiness, dizziness, somnolence, hypothermia, respiratory depression, seizures, rostral progression of hypotonia, and loss of consciousness progressing to coma), which may appear suddenly or insidiously, especially during the initial screening and dose-titration phase of treatment, and during reintroduction of therapy after a period of interruption.

Mechanism of Action

Inhibits the transmission of both monosynaptic and polysynaptic reflexes at the spinal cord level, possibly by hyperpolarization of primary afferent fiber terminals, with resultant relief of muscle spasticity

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Intrathecal bolus: 30 minutes to 1 hour; Continuous infusion: 6 to 8 hours after infusion initiation.

Peak effect: Intrathecal bolus: 4 hours (effects may last 4 to 8 hours); Continuous infusion: 24 to 48 hours.

Absorption (dose dependent): Oral: Rapid; absorption from the GI tract is thought to be dose dependent; in pediatric patients (age range: 2 to 17 years) with cerebral palsy, absorption from GI tract highly variable and delayed (reported time lag: 0.59 ± 0.28 hours) (He 2014).

Bioavailability: Oral: 74% (Agarwal 2015).

Protein binding: 30%.

Distribution: Volume of distribution: Pediatric patients (age range: 2 to 17 years: Oral: Highly variable: 1.16 L/kg with 43.5% interindividual variability (He 2014).

Metabolism: Hepatic (15% of dose) (He 2014).

Half-life elimination:

Oral:

Pediatric patients with cerebral palsy (age range: 2 to 17 years): 4.5 hours (He 2014).

Adults: Granules: 5.5 hours; Solution: ~5.7 hours; Suspension: ~5.6 hours; Tablets: 3.75 ± 0.96 hours (Brunton 2011).

Intrathecal: CSF elimination half-life: 1.51 hours over the first 4 hours.

Time to peak, serum: Oral: 1 hour (0.5 to 4 hours) (Brunton 2011); Solution: 0.75 hours; Suspension: 1 hour.

Excretion: Urine (>70% as unchanged drug) and feces (Brunton 2011).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Lioresal;
  • (AR) Argentina: Baclodox | Baclofeno Cevallos | Baclox | Bafen | Baltic | Flimab | Lioresal | Lioresal intratecal | Roclofeno;
  • (AT) Austria: Baclofen meduna | Baclofen sintetica | Lioresal;
  • (AU) Australia: Apo-baclofen | Baclo | Baclohexal | Bacthecal | Clofen | Cm baclofen | Dbl baclofen | Lioresal | Sintetica baclofen intrathecal | Stelax | Tw baclofen;
  • (BD) Bangladesh: Bacaid | Bacben | Bacifen | Backtone | Baclobac | Baclodol | Bacloflex | Baclon | Bacmax | Bacofen | Bactab | Beclo | Beclovan | Beklo | C Bac | Easybak | Fenobac | Flexibac | Flexifen | Flexilax | Flexiril | Liofen | Liorel | Lioresal | Liosal | Lirosal | Lospan | Maxolax | Muslofen | Mylofen | Myobac | Myorel | Reflexen | Relmas | Relofen | Rembac | Restobac | Skelofen | Smr | Spafen | Spaflex | Spakem | Spinafen | Spinofen | Starbac | Xanbac | Zerolent;
  • (BE) Belgium: Baclofen Aguettant | Baclofen merck-generics | Lioresal | Lioresal intrathec | Spacyr;
  • (BG) Bulgaria: Baclofen pharmadvice;
  • (BR) Brazil: Baclofeno | Baclon | Lioresal;
  • (CH) Switzerland: Baclocalm | Baclofen intrathecal sintetica | Baclofen sintetica | Lioresal;
  • (CI) Côte d'Ivoire: Lioresal;
  • (CL) Chile: Baclofeno | Cetril | Lioresyl;
  • (CN) China: Lioresal | Shu fen | Spinax | Zufen;
  • (CO) Colombia: Baclosan | Balanfen | Balyria | Distentia | Lioresal | Spastifen;
  • (CZ) Czech Republic: Baclofen meduna;
  • (DE) Germany: Baclaxiro | Baclofen AL | Baclofen dura | Baclofen meduna | Baclofen neuraxpharm | Baclofen sintetica | Baclofen Sun | Gablofen | Lebic | Lioresal;
  • (EC) Ecuador: Baclofeno | Diafen | Lioresal;
  • (EE) Estonia: Baclofen meduna | Baclofen sintetica | Baclophen | Baclosal | Lioresal | Lioresal intrathecal;
  • (EG) Egypt: Lioresal | Mylobac;
  • (ES) Spain: Lioresal;
  • (FI) Finland: Baclofen Merck NM | Baclofen sintetica | Baclon | Baclopar | Baklofen mylan | Lioresal;
  • (FR) France: Baclocur | Baclofene aguettant | Baclofene eg | Baclofene irex | Baclofene sun | Lioresal;
  • (GB) United Kingdom: Baclofen almus | Baclofen arrow | Baclofen berk | Baclofen cox | Baclofen Focus | Baclofen kent | Baclofen sandoz | Baclofen Teva | Baclospas | Balgifen | Gablofen | Lioresal | Lyflex | Relamex | Trav baclofen;
  • (GR) Greece: Miorel | Vioridon;
  • (HK) Hong Kong: Apo-baclofen | Apt Baclofen | Lioresal | Pms baclofen | Qualisal;
  • (HR) Croatia: Lioresal;
  • (HU) Hungary: Baclofen sintetica | Lioresal;
  • (ID) Indonesia: Lioresal;
  • (IE) Ireland: Baclopar | Lioresal;
  • (IL) Israel: Baclosal | Lioresal;
  • (IN) India: Bacfen | Bacfen xl | Baclesta | Baclocare | Baclof | Bacloren | Baclorest | Baclosol | Baclosure | Baclosure xl | Baclotab | Baclotop | Baczin | Bolofen | Chinofen | Fenbac xr | Gleefen | Liofen | Lioresal | Spinospas | Tefsole;
  • (IT) Italy: Baclofene bioindustria | Baclofene doc | Baclofene Mylan | Lioresal;
  • (JO) Jordan: Baclocalm | Lioresal;
  • (JP) Japan: Gabalon | Lioresal | Siobarofen | Torobamin | Torobamin choseido;
  • (KE) Kenya: Balcon;
  • (KR) Korea, Republic of: Baclafon | Baclan | Baclen | Baclfen | Baclon | Bacron | Baken | Bancloven | Barapa | Baront | Baropan | Baropen | Bigafen | Chinofen | Curofen | Daewoo baclofen | Dapro | Dongkoo baclofen | Gl baclofen | Handok baclofen | Hawon baclofen | Lioresal | Newgenpharm baclofen | Prex | Prinda | Rexfen | Samsung baclofen;
  • (KW) Kuwait: Lioresal;
  • (LB) Lebanon: Lioresal;
  • (LT) Lithuania: Lioresal | Lioresal intrathec;
  • (LU) Luxembourg: Lioresal;
  • (LV) Latvia: Baclofen ratiopharm | Baclosal | Lioresal;
  • (MA) Morocco: Lioresal;
  • (MX) Mexico: Mylinax;
  • (MY) Malaysia: Baclofen sintetica | Clofen | Liobac | Lioresal | Musafen | Pms baclofen;
  • (NG) Nigeria: Baclofen bp;
  • (NL) Netherlands: Baclofen Actavis | Baclofen sintetica | Baclofen Teva | Gablofen | Lioresal;
  • (NO) Norway: Baclofen intrathecal | Baclofen nmd grossist | Baclofen sintetica | Baklofen | Lionova | Lioresal;
  • (NZ) New Zealand: Alpha-baclofen | Lioresal | Pacifen;
  • (PE) Peru: Baclodrint | Baclofeno | Espast;
  • (PH) Philippines: Baclo | Lioresal | Liosal | Onelaxant R | Trilaxant;
  • (PK) Pakistan: Aerofin | Bacfen | Bacgen | Baclast | Baclin | Bacmax | Baflex | Bakin | Beclotab | Biobec | Fexibil | Lioresal | Liorex;
  • (PL) Poland: Baclofen sintetica | Lioresal;
  • (PR) Puerto Rico: First baclofen | Gablofen | Lioresal | Lioresal DS | Ozobax;
  • (PT) Portugal: Baclofeno | Baclofeno generis | Lioresal;
  • (PY) Paraguay: Diafen | Lioresal;
  • (QA) Qatar: Baclocalm | Lioresal | Lyflex;
  • (RO) Romania: Lioresal;
  • (RU) Russian Federation: Baclasan | Baclosan;
  • (SA) Saudi Arabia: Apo-baclofen | Colmifen | Lioresal | Pms baclofen;
  • (SE) Sweden: Baclofen medical valley | Baklofen 2care4 | Baklofen Alternova | Baklofen Bluefish | Baklofen Merck NM | Baklofen mylan | Gablofen | Lionova | Lioresal;
  • (SG) Singapore: Apo-baclofen | Colmifen | Lioresal;
  • (SI) Slovenia: Baclofen polpharma | Fezea | Lioresal;
  • (TH) Thailand: Baclosal | Bafen | Centrafen | Fenisal | Liobac | Lioresal | Musclofen | Myofen;
  • (TN) Tunisia: Liorefen | Lioresal | Pms baclofen;
  • (TR) Turkey: Baclofen sintetica | Lioresal;
  • (TW) Taiwan: Baclon | Bacone | Bacton | Bafen | Balax | Befon | Colmifen | Gabalon | Gablofen | Legafen | Lioresal | Maclofen | Mulax | Muscofen | Pacifen | Pickton | Solofen | Spinax | Sugei;
  • (UY) Uruguay: Baclof | Baclopert | Diafen | Lioresal;
  • (VN) Viet Nam: Bacfenz | Baclopain | Balisal | Bamifen | Maxcino | Prindax | Zabavnik;
  • (ZA) South Africa: Aspen baclofen | Bacentra intrathecal | Baclofen unichem | Lioresal | Norton-baclofen | Teva baclofen
  1. Addolorato G, Leggio L, Ferrulli A, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011;46(3):312-317. doi:10.1093/alcalc/agr017 [PubMed 21414953]
  2. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915-1922. doi:10.1016/S0140-6736(07)61814-5 [PubMed 18068515]
  3. Agarwal SK, Kriel RL, Cloyd JC, et al. A pilot study assessing pharmacokinetics and tolerability of oral and intravenous baclofen in healthy adult volunteers. J Child Neurol. 2015;30(1):37-41. doi:10.1177/0883073814535504 [PubMed 25028414]
  4. Aisen ML, Dietz M, McDowell F, Kutt H. Baclofen toxicity in a patient with subclinical renal insufficiency. Arch Phys Med Rehabil. 1994;75(1):109-111. [PubMed 8291951]
  5. Alden TD, Lytle RA, Park TS, Noetzel MJ, Ojemann JG. Intrathecal baclofen withdrawal: a case report and review of the literature. Childs Nerv Syst. 2002;18(9-10):522-525. doi:10.1007/s00381-002-0634-8 [PubMed 12382179]
  6. Al-Khodairy AT, Vuagnat H, Uebelhart D. Symptoms of recurrent intrathecal baclofen withdrawal resulting from drug delivery failure: a case report. Am J Phys Med Rehabil. 1999;78(3):272-277. doi:10.1097/00002060-199905000-00018 [PubMed 10340425]
  7. Alstermark C, Amin K, Dinn SR, et al. Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors. J Med Chem. 2008;51(14):4315-4320. doi:10.1021/jm701425k [PubMed 18578471]
  8. Alvis BD, Sobey CM. Oral baclofen withdrawal resulting in progressive weakness and sedation requiring intensive care admission. Neurohospitalist. 2017;7(1):39-40. doi:10.1177/1941874416637404 [PubMed 28042369]
  9. American Pain Society (APS). Principles of Analgesic Use. 7th ed. American Pain Society; 2016.
  10. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. [PubMed 27060684]
  11. Arima H, Oiso Y. Positive effect of baclofen on body weight reduction in obese subjects: a pilot study. Intern Med. 2010;49(19):2043-2047. doi:10.2169/internalmedicine.49.3918 [PubMed 20930428]
  12. ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.
  13. Auffret M, Rolland B, Deheul S, et al; CAMTEA Team. Severe tinnitus induced by off-label baclofen. Ann Pharmacother. 2014;48(5):656-659. doi:10.1177/1060028014525594 [PubMed 24577148]
  14. Baclofen tablet [prescribing information]. Memphis, TN: Northstar Rx LLC; October 2020.
  15. Baclofen tablets [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; April 2021.
  16. Baclofen tablets [prescribing information]. Amityville, NJ: Innogenix LLC; June 2021.
  17. Bence C, Cottencin O, Deheul S, Gautier S, Bordet R, Rolland B. Baclofen-induced edema in alcohol use disorders. J Clin Pharmacol. 2014 ;54(4):478-481. doi:10.1002/jcph.233 [PubMed 24293402]
  18. Berweck S, Lütjen S, Voss W, et al. Use of intrathecal baclofen in children and adolescents: interdisciplinary consensus table 2013. Neuropediatrics. 2014;45(5):294-308. [PubMed 25188830]
  19. Boster AL, Adair RL, Gooch JL, et al. Best practices for intrathecal baclofen therapy: dosing and long-term management. Neuromodulation. 2016;19(6):623-631. doi:10.1111/ner.12388 [PubMed 27433993]
  20. Boullata JI, Carrera AL, Harvey L, et al. ASPEN safe practices for enteral nutrition therapy. JPEN J Parenter Enteral Nutr. 2017;41(1):15-103. doi:10.1177/0148607116673053 [PubMed 27815525]
  21. Boullata JI. Guidebook on Enteral Medication Administration. American Society for Parenteral and Enteral Nutrition; 2019.
  22. Boz C, Velioglu S, Bulbul I, Ozmenoglu M. Baclofen is effective in intractable hiccups induced by brainstem lesions. Neurol Sci. 2001;22(5):409. [PubMed 11917982]
  23. Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. McGraw-Hill Medical; 2011.
  24. Carda S, Cazzaniga M, Taiana C, Pozzi R. Intrathecal baclofen bolus complicated by deep vein thrombosis and pulmonary embolism. A case report. Eur J Phys Rehabil Med. 2008;44(1):87-88. [PubMed 18385632]
  25. Chauvin KJ, Blake PG, Garg AX, et al. Baclofen has a risk of encephalopathy in older adults receiving dialysis. Kidney Int. 2020;S0085-2538(20)30552-4. doi:10.1016/j.kint.2020.04.047 [PubMed 32450156]
  26. Chen KS, Bullard MJ, Chien YY, Lee SY. Baclofen toxicity in patients with severely impaired renal function. Ann Pharmacother. 1997;31(11):1315-1320. doi:10.1177/106002809703101108 [PubMed 9391686]
  27. Chen YC, Chang CT, Fang JT, Huang CC. Baclofen neurotoxicity in uremic patients: is continuous ambulatory peritoneal dialysis less effective than intermittent hemodialysis? Ren Fail. 2009;25(2):297-305. doi:10.1081/jdi-120018730 [PubMed 12739836]
  28. Choo YM, Kim GB, Choi JY, et al. Severe respiratory depression by low-dose baclofen in the treatment of chronic hiccups in a patient undergoing CAPD. Nephron. 2000;86(4):546-547. doi:10.1159/000045866 [PubMed 11124626]
  29. Chou CL, Chen CA, Lin SH, Huang HH. Baclofen-induced neurotoxicity in chronic renal failure patients with intractable hiccups. South Med J. 2006;99(11):1308-1309. doi:10.1097/01.smj.0000247632.84949.27 [PubMed 17195438]
  30. Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Ann Intern Med. 2017;166(7):480-492. doi:10.7326/M16-2458 [PubMed 28192790]
  31. Committee on Safety of Medicines (CSM), Medicines Control Agency. Reminder: severe withdrawal reactions with baclofen. Curr Probl Pharmacovigilance. 1997;23:1-4. https://webarchive.nationalarchives.gov.uk/20090218060434/http://www.mhra.gov.uk/home/groups/pl-p/documents/publication/con2023229.pdf
  32. Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306-333. doi:10.1002/hep.30866 [PubMed 31314133]
  33. Dalton CM, Keenan E, Jarrett L, Buckley L, Stevenson VL. The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis. Mult Scler. 2008;14(4):571-572. doi: 10.1177/1352458507085552 [PubMed 18562512]
  34. Dapas F, Hartman SF, Martinez L, et al. Baclofen for the treatment of acute low-back syndrome. A double-blind comparison with placebo. Spine (Phila Pa 1976). 1985;10(4):345-349. doi:10.1097/00007632-198505000-00010 [PubMed 2931831]
  35. Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf. 2004;27(11):799-818. doi:10.2165/00002018-200427110-00004 [PubMed 15350152]
  36. Das S, Palappalllil DS, Purushothaman ST, Rajan V. An unusual case of baclofen abuse. Indian J Psychol Med. 2016;38(5):475-476. doi:10.4103/0253-7176.191383 [PubMed 27833235]
  37. Denys P, Mane M, Azouvi P, Chartier-Kastler E, Thiebaut JB, Bussel B. Side effects of chronic intrathecal baclofen on erection and ejaculation in patients with spinal cord lesions. Arch Phys Med Rehabil. 1998;79(5):494-496. doi:10.1016/s0003-9993(98)90061-2 [PubMed 9596387]
  38. Duncan SD, Devlin LA. Use of baclofen for withdrawal in a preterm infant. J Perinatol. 2013;33(4):327-328. doi:10.1038/jp.2012.107 [PubMed 23536044]
  39. El-Husseini A, Sabucedo A, Lamarche J, Courville C, Peguero A. Baclofen toxicity in patients with advanced nephropathy: proposal for new labeling. Am J Nephrol. 2011;34(6):491-495. doi:10.1159/000333247 [PubMed 22041434]
  40. Eriksson G, Swahn CG. Concentrations of baclofen in serum and breast milk from a lactating woman. Scand J Clin Lab Invest. 1981;41(2):185-187. doi:10.3109/00365518109092032 [PubMed 7313501]
  41. Expert opinion. Senior Enteral Feeding Tube Editorial Team: Joseph I. Boullata, PharmD, RPh, CNS-S, FASPEN, FACN; Peggi A. Guenter PhD, RN, FASPEN; Kathleen Gura, PharmD, BCNSP, FASHP, FASPEN, FPPA, FMSHP; Mark G. Klang MS, RPh, BCNSP, PhD, FASPEN; Linda Lord, NP, ACNP-BC, CNSC, FASPEN.
  42. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  43. Fleqsuvy (baclofen) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals Inc; February 2023.
  44. Freeman EH, Delaney RM. Neonatal baclofen withdrawal: A case report of an infant presenting with severe feeding difficulties. J Pediatr Nurs. 2016;31(3):346-349. doi:10.1016/j.pedn.2015.12.004. [PubMed 26810267]
  45. Gablofen (baclofen) [prescribing information]. Bethlehem, PA: Primal Critical Care Inc; April 2021.
  46. Galvez-Jimenez N. Symptom-based management of amyotrophic lateral sclerosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 6, 2022.
  47. Gee SW, Outsen S, Becknell B, Schwaderer AL. Baclofen toxicity responsive to hemodialysis in a pediatric patient with acute kidney injury. J Pediatr Intensive Care. 2016;5(1):37-40. doi:10.1055/s-0035-1568151. [PubMed 31110881]
  48. Ghosh S, Bhuyan D. Baclofen abuse due to its hypomanic effect in patients with alcohol dependence and comorbid major depressive disorder. Clin Psychopharmacol Neurosci. 2017;15(2):187-189. doi:10.9758/cpn.2017.15.2.187 [PubMed 28449569]
  49. Ginsburg GM, Lauder AJ. Progression of scoliosis in patients with spastic quadriplegia after the insertion of an intrathecal baclofen pump. Spine (Phila Pa 1976). 2007;32(24):2745-2750. doi:10.1097/BRS.0b013e31815a5219 [PubMed 18007255]
  50. Goyal V, Laisram N, Wadhwa RK, Kothari SY. Prospective randomized study of oral diazepam and baclofen on spasticity in cerebral palsy. J Clin Diagn Res. 2016;10(6):RC01-RC5. doi:10.7860/JCDR/2016/17067.7975 [PubMed 27504360]
  51. Grande LA, Loeser JD, Samii A. Recurrent transient global amnesia with intrathecal baclofen. Anesth Analg. 2008;106(4):1284-1287, table of contents. doi:10.1213/ane.0b013e318165e1c6 [PubMed 18349207]
  52. Grant JA, Steiner EM, Johnson RH. Treatment of persistent hiccups. J Neurol Neurosurg Psychiatry. 1991;54(5):468. doi:10.1136/jnnp.54.5.468 [PubMed 1865216]
  53. Greenberg MI, Hendrickson RG. Baclofen withdrawal following removal of an intrathecal baclofen pump despite oral baclofen replacement. J Toxicol Clin Toxicol. 2003;41(1):83-85. doi:10.1081/clt-120018277 [PubMed 12645974]
  54. Guelaud C, Similowski T, Bizec JL, Cabane J, Whitelaw WA, Derenne JP. Baclofen therapy for chronic hiccup. Eur Respir J. 1995;8(2):235-237. doi:10.1183/09031936.95.08020235 [PubMed 7758557]
  55. Hadjiyannacos D, Vlassopoulos D, Hadjiconstantinou V. Treatment of intractable hiccup in haemodialysis patients with baclofen. Am J Nephrol. 2001;21(5):427-8. doi:10.1159/000046290 [PubMed 11684810]
  56. Hara T, Nakajima M, Sugano H, et al. Pregnancy and breastfeeding during intrathecal baclofen therapy - a case study and review. NMC Case Rep J. 2018;5(3):65-68. doi:10.2176/nmccrj.cr.2017-0191 [PubMed 30023142]
  57. He Y, Brunstrom-Hernandez JE, Thio LL, et al. Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. J Pediatr. 2014;164(5):1181-1188.
  58. Hemingway C, McGrogan J, Freeman JM. Energy requirements of spasticity. Dev Med Child Neurol. 2001;43(4):277-278. doi:10.1017/s0012162201000524 [PubMed 11305407]
  59. Hornyak JE, McGehee MJ, Kelly B, Lin C. Oral baclofen as a cause of sexual dysfunction: A report of 2 cases. Archives of Physical Medicine and Rehabilitation. 2005;86(9):E39, Poster 197. https://www.archives-pmr.org/action/showPdf?pii=S0003-9993%2805%2900809-9
  60. Isaac Z. Management of nonradicular neck pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 22, 2022.
  61. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208 [PubMed 10891521]
  62. Jophlin LL, Singal AK, Bataller R, et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol. 2024;119(1):30-54. doi:10.14309/ajg.0000000000002572 [PubMed 38174913]
  63. Karol DE, Muzyk AJ, Preud'homme XA. A case of delirium, motor disturbances, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature. Gen Hosp Psychiatry. 2011;33(1):84.e1-e2. doi:10.1016/j.genhosppsych.2010.10.003 [PubMed 21353141]
  64. Karthikeyan VS, Senthilkumaran K, Easwaran B, Rajbhaskar R. Intestinal pseudo-obstruction following oral baclofen: An unusual complication. J Pharmacol Pharmacother. 2015;6(3):169-171. doi:10.4103/0976-500X.162010 [PubMed 26312004]
  65. Katsinelos P, Pilpilidis J, Xiarchos P, et al. Baclofen therapy for intractable hiccups induced by ultraflex esophageal endoprosthesis. Am J Gastroenterol. 2000;95(10):2986-2987. doi:10.1111/j.1572-0241.2000.03216.x [PubMed 11051387]
  66. Khazneh E, Shamlawi A, Jebrin K, Hamdan Z, Sawalmeh O. Single-dose baclofen-induced neurotoxicity in a patient with end stage renal disease: case report. BMC Nephrol. 2018;19(1):352. doi:10.1186/s12882-018-1167-z [PubMed 30537935]
  67. Klang MG. Developing guidance for feeding tube administration of oral medications. JPEN J Parenter Enteral Nutr. 2023;47(4):519-540. doi:10.1002/jpen.2490 [PubMed 36847617]
  68. Lee J, Shin HS, Jung YS, Rim H. Two cases of baclofen-induced encephalopathy in hemodialysis and peritoneal dialysis patients. Ren Fail. 2013;35(6):860-862. doi:10.3109/0886022X.2013.794679 [PubMed 23682655]
  69. Lin HH, Barton N, Wiegand TJ. Baclofen distribution into breast milk - a potential for toxicity? J Med Toxicol. 2014;10:86.
  70. Lioresal Intrathecal (baclofen) [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; August 2022.
  71. Lioresal Intrathecal (baclofen) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; May 2020.
  72. Lioresal tablets (baclofen) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; May 2020.
  73. Locatelli F, Formica F, Galbiati S, et al. Polysomnographic analysis of a pediatric case of baclofen-induced central sleep apnea. J Clin Sleep Med. 2019;15(2):351-354. doi:10.5664/jcsm.7644 [PubMed 30736882]
  74. Lois F, Wallemacq P, de Tourtchaninoff M, et al. Prolonged unconsciousness in a patient on automated peritoneal dialysis. Eur J Emerg Med. 2006;13(6):361-363. doi:10.1097/01.mej.0000217992.32235.ff [PubMed 17091060]
  75. Lubsch L, Habersang R, Haase M, Luedtke S. Oral baclofen and clonidine for treatment of spasticity in children. J Child Neurol. 2006;21(12):1090-1092. doi:10.1177/7010.2006.00134 [PubMed 17156708]
  76. Lyvispah (baclofen) [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; April 2023.
  77. Marino RA. Baclofen therapy for intractable hiccups in pancreatic carcinoma. Am J Gastroenterol. 1998;93(10):2000. doi: 10.1111/j.1572-0241.1998.02000.x [PubMed 9772082]
  78. McGehee M, Hornyak JE, Lin C, Kelly BM. Baclofen-induced sexual dysfunction. Neurology. 2006;67(6):1097-1098. doi:10.1212/01.wnl.0000237332.25528.ac [PubMed 17000991]
  79. Medical Advisory Secretariat. Intrathecal baclofen pump for spasticity: an evidence-based analysis. Ont Health Technol Assess Ser. 2005;5(7):1-93. [PubMed 23074476]
  80. Méndez-Lucena C, Chacón Peña J, García-Moreno JM. Intrathecal baclofen for dystonia treatment during pregnancy: a case report. Neurologia. 2016;31(2):131-132. doi:10.1016/j.nrl.2014.04.008 [PubMed 24851698]
  81. Meulendijks D, Khan S, Koks CH, Huitema AD, Schellens JH, Beijnen JH. Baclofen overdose treated with continuous venovenous hemofiltration. Eur J Clin Pharmacol. 2015;71(3):357-361. doi:10.1007/s00228-014-1802-y [PubMed 25567218]
  82. Milla PJ, Jackson AD. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res. 1977;5(6):398-404. doi:10.1177/030006057300100203 [PubMed 338390]
  83. Mirijello A, Addolorato G, D'Angelo C, et al. Baclofen in the treatment of persistent hiccup: a case series. Int J Clin Pract. 2013;67(9):918-921. doi:10.1111/ijcp.12184 [PubMed 23834241]
  84. Mohammed I, Hussain A. Intrathecal baclofen withdrawal syndrome- a life-threatening complication of baclofen pump: a case report. BMC Clin Pharmacol. 2004;4:6. doi:10.1186/1472-6904-4-6 [PubMed 15301690]
  85. Morant A, Noé E, Boyer J, et al. Paralytic ileus: a complication after intrathecal baclofen therapy. Brain Inj. 2006;20(13-14):1451-1454. doi:10.1080/02699050601082016 [PubMed 17378237]
  86. Morton CM, Rosenow J, Wong C, Kirschner KL. Intrathecal baclofen administration during pregnancy: a case series and focused clinical review. PM R. 2009;1(11):1025-1029. doi:10.1016/j.pmrj.2009.07.010 [PubMed 19942189]
  87. Olek MJ, Narayan RM, Frohman EM, Frohman TC. Symptom management of multiple sclerosis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 6, 2022.
  88. Olivier PY, Joyeux-Faure M, Gentina T, et al. Severe central sleep apnea associated with chronic baclofen therapy: A case series. Chest. 2016;149(5):e127-e131. doi:10.1016/j.chest.2015.10.001 [PubMed 27157226]
  89. O'Rourke F, Steinberg R, Ghosh P, Khan S. Withdrawal of baclofen may cause acute confusion in elderly patients. BMJ. 2001;323(7317):870. [PubMed 11597980]
  90. Ozobax (baclofen) [prescribing information]. Athens, GA: Metacel Pharmaceuticals LLC; May 2020.
  91. Ozobax DS (baclofen) [prescribing information]. Athens, GA: Metacel Pharmaceuticals LLC; September 2023.
  92. Panagopoulos D, Apostolopoulou K, Themistocleous M. Severe neuromuscular scoliosis implicated by dysfunction of intrathecal baclofen pump: Case report and review of the literature. World Neurosurg. 2020;134:390-395. doi:10.1016/j.wneu.2019.11.027 [PubMed 31733394]
  93. Pathak LK, Athavale A, Martinez I. Baclofen-induced toxicity in renal disease with neurotoxicity and skin rash. Proc (Bayl Univ Med Cent). 2019;32(3):425-426. doi:10.1080/08998280.2019.1618659 [PubMed 31384209]
  94. Peces R, Navascués RA, Baltar J, Laurés AS, Alvarez-Grande J. Baclofen neurotoxicity in chronic haemodialysis patients with hiccups. Nephrol Dial Transplant. 1998;13(7):1896-1897. [PubMed 9681766]
  95. Pelissier F, de Haro L, Cardona F, et al. Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008-2013. Clin Toxicol (Phila). 2017;55(4):275-284. doi:10.1080/15563650.2017.1284330 [PubMed 28152635]
  96. Porter LM, Merrick SS, Katz KD. Baclofen toxicity in a patient with hemodialysis-dependent end-stage renal disease. J Emerg Med. 2017;52(4):e99-e100. doi:10.1016/j.jemermed.2016.09.025 [PubMed 27789113]
  97. Quality Standards Subcommittee of the American Academy of Neurology (AAN) and the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336-343. doi: 10.1212/WNL.0b013e3181cbcd2f [PubMed 20101040]
  98. Ratnayaka BD, Dhaliwal H, Watkin S. Drug points: Neonatal convulsions after withdrawal of baclofen. BMJ. 2001;323(7304):85. doi:10.1136/bmj.323.7304.85 [PubMed 11451783]
  99. Refer to manufacturer's labeling.
  100. Reis PV, Vieira CR, Midões AC, Rebelo V, Barbosa P, Gomes A. Intrathecal baclofen infusion pumps in the treatment of spasticity: A retrospective cohort study in a Portuguese Centre. Acta Med Port. 2019;32(12):754-759. doi:10.20344/amp.10482 [PubMed 31851884]
  101. Rifici C, D'Aleo G, D'Aleo P, Bramanti P, Saltuari L, Kofler M. Cardiovascular alterations heralded by intrathecal baclofen bolus. NeuroRehabilitation. 2011;28(4):389-393. doi:10.3233/NRE-2011-0668 [PubMed 21725173]
  102. Riva-baclofen (baclofen) [product monograph]. Blainville, Canada: Laboratoire Riva Inc; July 2020.
  103. Roberts JK, Westphal S, Sparks MA. Iatrogenic Baclofen neurotoxicity in ESRD: recognition and management. Semin Dial. 2015;28(5):525-529. doi:10.1111/sdi.12400. [PubMed 26096760]
  104. Saddichha S, Jayaram N, Manjunatha N, Benegal V. Baclofen-induced morbiliform rashes: a case series. J Clin Pharmacol. 2011;51(12):1733-1734. doi:10.1177/0091270010385936 [PubMed 21119092]
  105. Salim SA, Thomas L, Achanti A, et al. Baclofen-induced neurotoxicity in patients with compromised renal function: Review. Int J Clin Pharmacol Ther. 2018;56(10):467-475. doi:10.5414/CP203243 [PubMed 12769509]
  106. Saulino M, Anderson DJ, Doble J, et al. Best practices for intrathecal baclofen therapy: Troubleshooting. Neuromodulation. 2016;19(6):632-641. doi:10.1111/ner.12467 [PubMed 27434299]
  107. Saval A, Chiodo AE. Sexual dysfunction associated with intrathecal baclofen use: a report of two cases. J Spinal Cord Med. 2008;31(1):103-105. doi:10.1080/10790268.2008.11753989 [PubMed 18533420]
  108. Scheinberg A, Hall K, Lam LT, O'Flaherty S. Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study. J Paediatr Child Health. 2006;42(11):715-20. doi:10.1111/j.1440-1754.2006.00957.x [PubMed 17044900]
  109. Sechrist C, Kinsman S, Cain N. Profound bradycardia after intrathecal baclofen injection in a patient with hydranencephaly. Pediatr Neurol. 2015;53(6):532-534. doi:10.1016/j.pediatrneurol.2015.08.010 [PubMed 26411756]
  110. Seker MM, Aksoy S, Ozdemir NY, et al. Successful treatment of chronic hiccup with baclofen in cancer patients. Med Oncol. 2012;29(2):1369-1370. doi:10.1007/s12032-011-9910-3 [PubMed 21442315]
  111. Siegfried RN, Jacobson L, Chabal C. Development of an acute withdrawal syndrome following the cessation of intrathecal baclofen in a patient with spasticity. Anesthesiology. 1992;77(5):1048-1050. doi:10.1097/00000542-199211000-00034 [PubMed 1443727]
  112. Singh NK, Agarwal A, Salazar L, Henkle JQ. Osborn waves in hypothermia induced by baclofen overdose. BMJ Case Rep. 2009;2009:bcr10.2008.1142. doi:10.1136/bcr.10.2008.1142 [PubMed 21686448]
  113. Su W, Yegappan C, Carlisle EJ, Clase CM. Reduced level of consciousness from baclofen in people with low kidney function. BMJ. 2009;339:b4559. doi:10.1136/bmj.b4559 [PubMed 20044395]
  114. Swigar ME, Bowers MB. Baclofen withdrawal and neuropsychiatric symptoms: a case report and review of other case literature. Compr Psychiatry. 1986;27(4):396-400. doi:10.1016/0010-440x(86)90016-7 [PubMed 3731773]
  115. Tandon SS, Hoskins I, Azhar S. Intrathecal baclofen pump - a viable therapeutic option in pregnancy. Obstet Med. 2010;3(3):119-120. doi:10.1258/om.2010.100016 [PubMed 27576877]
  116. Turkyilmaz A, Eroglu A. Use of baclofen in the treatment of esophageal stent-related hiccups. Ann Thorac Surg. 2008;85(1):328-330. doi:10.1016/j.athoracsur.2007.07.059 [PubMed 18154840]
  117. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM; Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the Cochrane Collaboration. Spine (Phila Pa 1976). 2003;28(17):1978-1992. doi:10.1097/01.BRS.0000090503.38830.AD [PubMed 12973146]
  118. Vlavonou R, Perreault MM, Barrière O, et al. Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations. J Clin Pharmacol. 2014;54(5):584-592. doi:10.1002/jcph.247 [PubMed 24414993]
  119. Walker KR, Novotny SA, Krach LE. Does intrathecal baclofen therapy increase prevalence and/or progression of neuromuscular scoliosis? Spine Deform. 2017;5(6):424-429. doi:10.1016/j.jspd.2017.03.006 [PubMed 29050720]
  120. Weißhaar GF, Hoemberg M, Bender K, et al. Baclofen intoxication: a "fun drug" causing deep coma and nonconvulsive status epilepticus--a case report and review of the literature. Eur J Pediatr. 2012;171(10):1541-1547. doi:10.1007/s00431-012-1780-y [PubMed 22729246]
  121. White R, Bradnam V; British Pharmaceutical Nutrition Group. Handbook of Drug Administration via Enteral Feeding Tubes. 3rd ed. Pharmaceutical Press; 2015.
  122. Wolf E, Kothari NR, Roberts JK, Sparks MA. Baclofen toxicity in kidney disease. Am J Kidney Dis. 2018;71(2):275-280. doi:10.1053/j.ajkd.2017.07.005 [PubMed 28899601]
  123. Wu VC, Lin SL, Lin SM, Fang CC. Treatment of baclofen overdose by haemodialysis: a pharmacokinetic study. Nephrol Dial Transplant. 2005;20(2):441-443. doi:10.1093/ndt/gfh297 [PubMed 15615812]
  124. Yang TF, Wang JC, Chiu JW, Lai CJ, Chan RC, Lee SS. Ultrasound-guided refilling of an intrathecal baclofen pump--a case report. Childs Nerv Syst. 2013;29(2):347-349. doi: 10.1007/s00381-012-1953-z [PubMed 23129445]
  125. Zeman A, Hoefeijzers S, Milton F, Dewar M, Carr M, Streatfield C. The GABAB receptor agonist, baclofen, contributes to three distinct varieties of amnesia in the human brain - A detailed case report. Cortex. 2016;74:9-19. doi:10.1016/j.cortex.2015.10.005 [PubMed 26599496]
  126. Zhang C, Zhang R, Zhang S, Xu M, Zhang S. Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial. Trials. 2014;15:295. doi:10.1186/1745-6215-15-295 [PubMed 25052238]
Topic 9062 Version 789.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟